Log in

Relevant bibliographies by topics / Cardiovascular Diseases – therapy / Journal articles

To see the other types of publications on this topic, follow the link: Cardiovascular Diseases – therapy.

Journal articles on the topic 'Cardiovascular Diseases – therapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cardiovascular Diseases – therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Topolyanskaya, Topolyanskaya S. V. "Hyperuricemia and cardiovascular diseases." Therapy 7_2020 (October 26, 2020): 71–82. http://dx.doi.org/10.18565/therapy.2020.7.71-82.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Roytberg, Roytberg G. E., Slastnikova I. D. Slastnikova, and Davydova A. Sh Davydova. "Coronary artery calcium: prognostic value for cardiovascular and non-cardiovascular diseases." Therapy 6_2021 (August 23, 2021): 81–90. http://dx.doi.org/10.18565/therapy.2021.6.81-90.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Eliseev, Eliseev M. S. "Cardiovascular diseases in gout and urate-lowering therapy." Therapy 1_2021 (February 19, 2021): 108–15. http://dx.doi.org/10.18565/therapy.2021.1.108-115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gruchala, Marcin, Himadri Roy, Shalini Bhardwaj, and Seppo Yla-Herttuala. "Gene Therapy for Cardiovascular Diseases." Current Pharmaceutical Design 10, no. 4 (2004): 407–23. http://dx.doi.org/10.2174/1381612043453379.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Tamirisa, Kamala, and Debabrata Mukherjee. "Gene Therapy in Cardiovascular Diseases." Current Gene Therapy 2, no. 4 (2002): 427–35. http://dx.doi.org/10.2174/1566523023347643.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tateno, Kaoru, Tohru Minamino, Junji Moriya, et al. "Cell Therapy for Cardiovascular Diseases." Annals of Vascular Diseases 1, no. 2 (2008): 66–79. http://dx.doi.org/10.3400/avd.avdsr00108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Phillips, M., Jessica Costales, Robert Lee, Edilamar Oliveira, and Andrew Burns. "Antisense Therapy for Cardiovascular Diseases." Current Pharmaceutical Design 21, no. 30 (2015): 4417–26. http://dx.doi.org/10.2174/1381612821666150803150402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mattson, Craig N. "Drug Therapy in Cardiovascular Diseases." Mayo Clinic Proceedings 61, no. 11 (1986): 919. http://dx.doi.org/10.1016/s0025-6196(12)62625-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

NABEL, E. "Gene therapy for cardiovascular diseases." Journal of Nuclear Cardiology 6, no. 1 (1999): 69–75. http://dx.doi.org/10.1016/s1071-3581(99)90066-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

BAUTERS, C. "Gene therapy for cardiovascular diseases." European Heart Journal 16, no. 9 (1995): 1166–68. http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a061070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Brugada, Ramon, and Robert Roberts. "Gene therapy for cardiovascular diseases." Expert Opinion on Therapeutic Patents 10, no. 9 (2000): 1385–93. http://dx.doi.org/10.1517/13543776.10.9.1385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

IP, JOHN H., BERNARDO STEIN, VALENTIN FUSTER, and LINA BADIMON. "Antithrombotic Therapy in Cardiovascular Diseases." Annals of the New York Academy of Sciences 614, no. 1 (1991): 289–311. http://dx.doi.org/10.1111/j.1749-6632.1991.tb43711.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Yla-Herttuala, Seppo. "Gene Therapy for Cardiovascular Diseases." Annals of Medicine 28, no. 2 (1996): 89–94. http://dx.doi.org/10.3109/07853899609092931.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Snowden, Margaret M., and Robert I. Grove. "Gene therapy for cardiovascular diseases." Expert Opinion on Therapeutic Patents 8, no. 5 (1998): 509–20. http://dx.doi.org/10.1517/13543776.8.5.509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Silke, Bernard. "Drug therapy in cardiovascular diseases." International Journal of Cardiology 14, no. 3 (1987): 392. http://dx.doi.org/10.1016/0167-5273(87)90221-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Avdeeva, Avdeeva I. V., Burko N. V. Burko, Makarova Kar N. Makarova, Makarova Kr N. Makarova, and Oleynikov V. E. Oleynikov. "COVID-19 and cardiovascular diseases: a dangerous tandem." Therapy 5_2021 (June 21, 2021): 96–102. http://dx.doi.org/10.18565/therapy.2021.5.96-102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bell, Dawn M., Thomas E. Johns, and Larry M. Lopez. "Endothelial Dysfunction: Implications for Therapy of Cardiovascular Diseases." Annals of Pharmacotherapy 32, no. 4 (1998): 459–70. http://dx.doi.org/10.1345/aph.17084.

Full text

Abstract:

OBJECTIVE: To review current literature regarding endothelial dysfunction in cardiovascular diseases and examine implications of these findings for the treatment of various cardiovascular disorders. DATA SOURCE: A MEDLINE search of basic science articles pertinent to understanding the role of the endothelium in the atherosclerotic process and of clinical trials examining the presence and treatment of impaired endothelium-dependent vascular relaxation was conducted. STUDY SELECTION: Selected basic science articles and reviews were included to explain the foundation for subsequent clinical trial

APA, Harvard, Vancouver, ISO, and other styles

18

Quarck, Rozenn, and Paul Holvoet. "Gene Therapy Approaches for Cardiovascular Diseases." Current Gene Therapy 4, no. 2 (2004): 207–23. http://dx.doi.org/10.2174/1566523043346499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Johnston, D. W. "Cognitive behaviour therapy for cardiovascular diseases." Zeitschrift f�r Kardiologie 89 (November 1, 2000): IX78—IX81. http://dx.doi.org/10.1007/s003920070035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bailar, John. "Hormone-Replacement Therapy and Cardiovascular Diseases." New England Journal of Medicine 349, no. 6 (2003): 521–22. http://dx.doi.org/10.1056/nejmp038110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tse, Hung-Fat. "Stem cell therapy in cardiovascular diseases." Cell Research 18, S1 (2008): S12. http://dx.doi.org/10.1038/cr.2008.102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Willerson, James T. "Stem cell therapy for cardiovascular diseases." Current Opinion in Cardiology 30, no. 3 (2015): 205–12. http://dx.doi.org/10.1097/hco.0000000000000156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Silvestre, Jean Sebastien. "STEM CELL THERAPY FOR CARDIOVASCULAR DISEASES." Artery Research 16, no. C (2016): 45. http://dx.doi.org/10.1016/j.artres.2016.10.146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Karamızrak, Neslihan. "Kardiyovasküler Hastalıklarda Müzik ile Terapi." Kosuyolu Heart Journal 22, no. 2 (2019): 120–25. http://dx.doi.org/10.5578/khj.68486.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sakakibara, Kenji, Masahiko Matsumoto, Masatake Katsu, and Shoji Suzuki. "Mediastinal Radiation Therapy-induced Multiple Cardiovascular Diseases." Internal Medicine 54, no. 6 (2015): 683–84. http://dx.doi.org/10.2169/internalmedicine.54.2314.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

MATSUBARA, Hiroaki, Hiroya MASAKI, Hiroshi KAMIHATA, and Toshiji IWASAKA. "Somatic Stem Cell Therapy for Cardiovascular Diseases." Journal of Kansai Medical University 55, no. 2-4 (2003): 155–61. http://dx.doi.org/10.5361/jkmu1956.55.2-4_155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

IMAI, T. "Treatment of Cardiovascular Diseases by Ryodoraku Therapy." Japanese Journal of Ryodoraku Medicine 37, no. 3 (1992): 71–74. http://dx.doi.org/10.17119/ryodoraku1986.37.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

AOKI, Motokuni, and Ryuichi MORISHITA. "HGF-treated Gene Therapy for Cardiovascular Diseases." Japanese Journal of Thrombosis and Hemostasis 10, no. 6 (1999): 435–43. http://dx.doi.org/10.2491/jjsth.10.435.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Cogle, Christopher R. "Bone Marrow Cell Therapy for Cardiovascular Diseases." Oncology & Hematology Review (US) 00, no. 01 (2007): 46. http://dx.doi.org/10.17925/ohr.2007.01.01.46.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Altman, Raul. "Controversies in Antithrombotic Therapy in Cardiovascular Diseases." Clinical and Applied Thrombosis/Hemostasis 4, no. 1 (1998): 11–24. http://dx.doi.org/10.1177/107602969800400105.

Full text

Abstract:

Antithrombotic treatment became an important point in human medical treatment. Dicoumarols, heparin, aspi rin, and more recently, direct antithrombins and platelet glyco protein IIb/IIIa receptor blockers are the most frequent medi cations used as antithrombotics. The role of these drugs in the treatment of cardiovascular diseases remains controversial. Low-dose aspirin (80-100 mg/day) should be used for second ary prevention in patients with a history of coronary disease. Primary prevention in patients with no risk factors is not rec ommended. Studies using oral anticoagulant therapy indicate

APA, Harvard, Vancouver, ISO, and other styles

31

Medvedev, V. E., E. A. Korovyakova, V. I. Frolova, and E. V. Gushanskaya. "Antidepressant therapy in patients with cardiovascular diseases." Neurology, Neuropsychiatry, Psychosomatics 11, no. 1 (2019): 131–40. http://dx.doi.org/10.14412/2074-2711-2019-1-131-140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Volterrani, Maurizio, Ferdinando Iellamo, Barbara Sposato, and Franco Romeo. "Uric acid lowering therapy in cardiovascular diseases." International Journal of Cardiology 213 (June 2016): 20–22. http://dx.doi.org/10.1016/j.ijcard.2015.08.088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

He, Nana, Yuelin Zhang, Shun Zhang, Dongjuan Wang, and Honghua Ye. "Exosomes: Cell-Free Therapy for Cardiovascular Diseases." Journal of Cardiovascular Translational Research 13, no. 5 (2020): 713–21. http://dx.doi.org/10.1007/s12265-020-09966-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Shirakawa, Kohsuke, and Motoaki Sano. "Osteopontin in Cardiovascular Diseases." Biomolecules 11, no. 7 (2021): 1047. http://dx.doi.org/10.3390/biom11071047.

Full text

Abstract:

Unprecedented advances in secondary prevention have greatly improved the prognosis of cardiovascular diseases (CVDs); however, CVDs remain a leading cause of death globally. These findings suggest the need to reconsider cardiovascular risk and optimal medical therapy. Numerous studies have shown that inflammation, pro-thrombotic factors, and gene mutations are focused not only on cardiovascular residual risk but also as the next therapeutic target for CVDs. Furthermore, recent clinical trials, such as the Canakinumab Anti-inflammatory Thrombosis Outcomes Study trial, showed the possibility of

APA, Harvard, Vancouver, ISO, and other styles

35

Dishart, Kate L., Lorraine M. Work, Laura Denby, and Andrew H. Baker. "Gene Therapy for Cardiovascular Disease." Journal of Biomedicine and Biotechnology 2003, no. 2 (2003): 138–48. http://dx.doi.org/10.1155/s1110724303209086.

Full text

Abstract:

The last decade has seen substantial advances in the development of gene therapy strategies and vector technology for the treatment of a diverse number of diseases, with a view to translating the successes observed in animal models into the clinic. Perhaps the overwhelming drive for the increase in vascular gene transfer studies is the current lack of successful long-term pharmacological treatments for complex cardiovascular diseases. The increase in cardiovascular disease to epidemic proportions has also led many to conclude that drug therapy may have reached a plateau in its efficacy and tha

APA, Harvard, Vancouver, ISO, and other styles

36

Flores, Alyssa M., Jianqin Ye, Kai-Uwe Jarr, Niloufar Hosseini-Nassab, Bryan R. Smith, and Nicholas J. Leeper. "Nanoparticle Therapy for Vascular Diseases." Arteriosclerosis, Thrombosis, and Vascular Biology 39, no. 4 (2019): 635–46. http://dx.doi.org/10.1161/atvbaha.118.311569.

Full text

Abstract:

Nanoparticles promise to advance strategies to treat vascular disease. Since being harnessed by the cancer field to deliver safer and more effective chemotherapeutics, nanoparticles have been translated into applications for cardiovascular disease. Systemic exposure and drug-drug interactions remain a concern for nearly all cardiovascular therapies, including statins, antithrombotic, and thrombolytic agents. Moreover, off-target effects and poor bioavailability have limited the development of completely new approaches to treat vascular disease. Through the rational design of nanoparticles, nan

APA, Harvard, Vancouver, ISO, and other styles

37

Jarwani, Bhavesh. "Cardiovascular disease and antiretroviral therapy." Journal of Global Infectious Diseases 11, no. 3 (2019): 91. http://dx.doi.org/10.4103/jgid.jgid_4_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Pelliccia, Antonio, Filippo M. Quattrini, Maria Rosaria Squeo, et al. "Cardiovascular diseases in Paralympic athletes." British Journal of Sports Medicine 50, no. 17 (2016): 1075–80. http://dx.doi.org/10.1136/bjsports-2015-095867.

Full text

Abstract:

BackgroundSport participation (SP) of individuals with impairments has recently grown exponentially. Scarce scientific data, however, exist regarding cardiovascular (CV) risk associated with competitive SP.ObjectiveAssessing the prevalence of CV abnormalities and the risk for SP in Paralympic athletes (PA).MethodsPA (n=267; 76% men), aged 35±9 years, engaged in 18 sport disciplines, with a spectrum of lesions including: spinal cord injury (paraplegia and spina bifida) (n=116); amputation, poliomyelitis, cerebral palsy and other neuromuscular and/or skeletal disorders (Les autres) or visual imp

APA, Harvard, Vancouver, ISO, and other styles

39

Acharya, Gayathri, Nurhasni Hasan, Jin-Wook Yoo, and Chi H. Lee. "Hormone Therapy and Delivery Strategies against Cardiovascular Diseases." Current Pharmaceutical Biotechnology 18, no. 4 (2017): 285–302. http://dx.doi.org/10.2174/1389201018666170224103306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Parolini, Cinzia, Marta Marchesi, and Giulia Chiesa. "HDL Therapy for the Treatment of Cardiovascular Diseases." Current Vascular Pharmacology 7, no. 4 (2009): 550–56. http://dx.doi.org/10.2174/157016109789043856.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Wang, Chao-Hung, Wen-Jin Cherng, and Subodh Verma. "Drawbacks to stem cell therapy in cardiovascular diseases." Future Cardiology 4, no. 4 (2008): 399–408. http://dx.doi.org/10.2217/14796678.4.4.399.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Rios, C. David, Yi Chu, Beverly L. Davidson, and Donald D. Heistad. "Ten steps to gene therapy for cardiovascular diseases." Journal of Laboratory and Clinical Medicine 132, no. 2 (1998): 104–11. http://dx.doi.org/10.1016/s0022-2143(98)90005-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Franceschini, G. "We-PL3:2 HDL therapy for cardiovascular diseases." Atherosclerosis Supplements 7, no. 3 (2006): 301. http://dx.doi.org/10.1016/s1567-5688(06)81220-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Calvert, John W., and David J. Lefer. "Clinical translation of nitrite therapy for cardiovascular diseases." Nitric Oxide 22, no. 2 (2010): 91–97. http://dx.doi.org/10.1016/j.niox.2009.11.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Thavendiranathan, Paaladinesh. "Primary Prevention of Cardiovascular Diseases With Statin Therapy." Archives of Internal Medicine 166, no. 21 (2006): 2307. http://dx.doi.org/10.1001/archinte.166.21.2307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Beaudry, Dominique, Kenneth E. Stone, Suzanne Wetherold, et al. "Statin therapy in cardiovascular diseases other than atherosclerosis." Current Atherosclerosis Reports 9, no. 1 (2007): 25–32. http://dx.doi.org/10.1007/bf02693937.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ibad, Awais, Rabia Khalid, and Paul D. Thompson. "Chelation therapy in the treatment of cardiovascular diseases." Journal of Clinical Lipidology 10, no. 1 (2016): 58–62. http://dx.doi.org/10.1016/j.jacl.2015.09.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Netiazhenko, V. Z. "Infusion therapy for cardiovascular diseases: the allowed limits." Infusion & Chemotherapy, no. 3.2 (December 15, 2020): 227–30. http://dx.doi.org/10.32902/2663-0338-2020-3.2-227-230.

Full text

Abstract:

Background. Analysis of the mortality structure of patients with coronavirus disease (COVID-19) had found that 69.2 % of non-survivors had hypertension. Comorbid diabetes mellitus (31.8 %) and coronary heart disease (28.2 %) were also common. During pandemic, it is necessary to maintain optimal cardiovascular therapy by continuing to administer its main drugs (acetylsalicylic acid, statins, β-blockers, angiotensin-converting enzyme inhibitors – ACEI). Objective. To describe infusion therapy (IT) for cerebrovascular and cardiovascular diseases in settings of the COVID-19 pandemic. M

APA, Harvard, Vancouver, ISO, and other styles

49

Gomonova, Gomonova V. V., Sayganov S. A. Sayganov, and Gumerova V. E. Gumerova. "Parameters of arterial stiffness in the stratification of the risk of cardiovascular diseases." Therapy 6_2019 (November 1, 2019): 50–56. http://dx.doi.org/10.18565/therapy.2019.6.50-56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sauvetre, EJ, MS Farid, and CV Diji. "Cardiovascular Diseases and Periodontal Treatment." Journal of Oral Health and Community Dentistry 2, no. 2 (2008): 25–29. http://dx.doi.org/10.5005/johcd-2-2-25.

Full text

Abstract:

ABSTRACT A Safe and effective periodontal treatment requires knowledge and understanding of the diseases specifically the cardiovascular ones, and the necessary modifications to periodontal therapy accordingly. Considering the high incidence of periodontal diseases in elderly individuals, the periodontist must be prepared to provide periodontal therapeutic support for an increasing number of cardiovascular patients. In this review, common cardiovascular disorders and associated periodontal issues would be discussed briefly.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!